2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-151982
    Tubulin polymerization-IN-39 98%
    Tubulin polymerization-IN-39 is a tubulin polymerization inhibitor (IC50: 4.9 μM). Tubulin polymerization-IN-39 occupies the colchicine-binding site. Tubulin polymerization-IN-39 inhibits cancer cell proliferation.
    Tubulin polymerization-IN-39
  • HY-151983
    Thrombin inhibitor 6 1628224-94-1 98%
    Thrombin inhibitor 6 is a potent thrombin inhibitor (IC50: 1 nM). Thrombin inhibitor 6 has the function as an anticoagulant.
    Thrombin inhibitor 6
  • HY-151996
    Tubulin inhibitor 31 98%
    Tubulin inhibitor 31 is a potent tubulin inhibitor with an IC50 value of 4 µM. Tubulin inhibitor 31 shows anti-proliferative activity. Tubulin inhibitor 31 inhibits the HUVEC migration.
    Tubulin inhibitor 31
  • HY-152087
    DCZ19931 2789629-84-9 98%
    DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling.
    DCZ19931
  • HY-152190
    JB002 30408-07-2 99.32%
    JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
    JB002
  • HY-15284R
    Prasugrel (Standard) 150322-43-3
    Prasugrel (Standard) is the analytical standard of Prasugrel. This product is intended for research and analytical applications. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel (Standard)
  • HY-15284S
    Prasugrel-d5 1127252-92-9 98%
    Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel-d5
  • HY-153011
    ROCK-IN-5 692870-25-0 ≥98.0%
    ROCK-IN-5 (compound I-B-37) is a potent inhibitor of ROCK, ERK, GSK, and AGC protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research.
    ROCK-IN-5
  • HY-153020
    HIF-PHD-IN-3 794582-71-1 ≥98.0%
    HIF-PHD-IN-3 (compound 4) is a potent hiPSC-CM cardioprotective scaffold. HIF-PHD-IN-3 can induce upregulation of heme oxygenase-1.
    HIF-PHD-IN-3
  • HY-153168
    Bemoradan 112018-01-6 98%
    Bemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart failure research.
    Bemoradan
  • HY-153183
    Lp-PLA2-IN-12 2637485-14-2 98%
    Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis.
    Lp-PLA2-IN-12
  • HY-153333
    A1/A3 AR antagonist 3 2665804-57-7 98%
    A1/A3 AR antagonist 3 is an A1R/A3R dual antagonist with high affinity at low-micromolar to low-nanomolar. A1/A3 AR antagonist 3 can be used for the research of chronic heart diseases.
    A1/A3 AR antagonist 3
  • HY-153452
    PCSK9-IN-16 2455424-51-6 98%
    PCSK9-IN-16 is a potent PCSK9 inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research.
    PCSK9-IN-16
  • HY-153453
    PCSK9-IN-17 2455424-72-1 98%
    PCSK9-IN-17 is a PCSK9 inhibitor. PCSK9-IN-17 can be used for the research of cholesterol metabolism (WO2020150474A1, compound 105).
    PCSK9-IN-17
  • HY-153458
    Orexin receptor modulator-1 2125735-57-9 98%
    Orexin receptor modulator-1 is an orexin receptor modulator. Orexin receptor modulator-1 can be used for the research of substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Orexin receptor modulator-1
  • HY-153464
    CXCR4-IN-1 2304750-48-7 98%
    CXCR4-IN-1 (Example C5) is a CXCR4 inhibitor (IC50: 20 nM). CXCR4-IN-1 can be used for research of cancer, HIV, diabetic retinopathy, inflammation, etc.
    CXCR4-IN-1
  • HY-153489
    ISIS 329993 827355-42-0
    ISIS 329993 (ISIS-CRPRx) is an antisense oligonucleotide targeting to C-reactive protein (CRP). ISIS-CRPRx has been tested in a rodent model of rheumatoid arthritis (RA) and was shown to improve the clinical signs of arthritis
    ISIS 329993
  • HY-153528
    DMAA 73671-86-0 98%
    DMAA is an indirect sympathomimetic amine. DMAA constricts blood vessels and raises blood pressure. DMAA can be used for neurological and cardiovascular disease research.
    DMAA
  • HY-153706
    URAT1 inhibitor 5 2102670-94-8 98%
    URAT1 inhibitor 5 (compound 16) is a potent URAT1 inhibitor. URAT1 inhibitor 5 can be used in research of hyperuricemia.
    URAT1 inhibitor 5
  • HY-153766
    PDE5-IN-9 157862-84-5 ≥98.0%
    PDE5-IN-9 (Compound 59) is a PDE5 inhibitor (IC50: 11.2 μM). PDE5-IN-9 shows interaction with Gln 817, Tyr 612, and Ala 767 amino acid residues. PDE5-IN-9 can be used for research of cardiovascular disease.
    PDE5-IN-9
Cat. No. Product Name / Synonyms Application Reactivity